U.S. FDA Says Shionogi Of Japan Makes Misleading Claims For Cedax
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA accused Japan's Shionogi of making misleading claims in its promotional material for the antibiotic Cedax (ceftibuten) for treating mild infections. The agency said Shionogi distributed promotional material for physicians without noting the drug's risks while claiming "excellent tolerability." According to FDA, Cedaxhas several side effects that were not mentioned in its promotional material. In a warning letter, the agency also said Shionogi claimed uses for the drug beyond the ranger of infections included in the agency's U.S. approval. (Click here for more
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.